molmed

News & Events

Stay update

Focus Live, Claudio Bordignon e Luigi Naldini "Geni che curano" ▾

Focus Live, Claudio Bordignon e Luigi Naldini "Geni che curano"

Location: Museo Scienza e Tecnologia Milano

MolMed at this event: Claudio Bordignon, fondatore di MolMed e Presidente del Scientific Advisory Board di MolMed

News & Events

Stay update

Claudio Bordignon: Gene & Cell Therapy, the new frontier of medicine. Festival della Scienza ▾

Claudio Bordignon: Gene & Cell Therapy, the new frontier of medicine. Festival della Scienza

Location: Genova, Palazzo Ducale Sala del Minor Consiglio

MolMed at this event: Incontro con Claudio Bordignon, modera Massimo Sideri

Investors

October 25th 2018 Ordinary and Extraordinary Shareholders Meeting Outcome

October 25th 2018 Ordinary and Extraordinary Shareholders Meeting Outcome ▾

Investors

Ordinary and extraordinary shareholders meeting October 25 2018

Ordinary and extraordinary shareholders meeting October 25 2018 ▾

Investors

Results from a new study on CAR T CD44v6 in in-vivo experimental models of lung carcinoma and melanoma confirm the high therapeutic potential of MolMed’s therapy also in solid tumors. The results have been presented today at the ESGCT

Results from a new study on CAR T CD44v6 in in-vivo experimental models of lung carcinoma and melanoma confirm the high therapeutic potential of MolMed’s therapy also in solid tumors. The results have been presented today at the ESGCT ▾

News & Events

Stay update

ESCGT (European Society of Gene & Cell Therapy) Congress 16-19 October Lausanne, Switzerland ▾

ESCGT (European Society of Gene & Cell Therapy) Congress 16-19 October Lausanne, Switzerland

Location: SwissTech, Lausanne

MolMed at this event: Oral presentation

Investors

MolMed: announcement with reference to the shareholders meeting of October 25th 2018.

MolMed: announcement with reference to the shareholders meeting of October 25th 2018. ▾

News & Events

Stay update

ARM Cell & Gene Meeting on the MESA ▾

ARM Cell & Gene Meeting on the MESA

Location:

La Jolla, California (USA), Ball Room 1 3th October 2018 11:45

MolMed at this event:

Company Presentation - Speech

Investors

Interim financial report as of September, 30th 2018

Interim financial report as of September, 30th 2018 ▾

Investors

MolMed participates at the first annual meeting of the International Academy for Clinical Hematology ("IACH"). The therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours presented at the summit.

MolMed participates at the first annual meeting of the International Academy for Clinical Hematology ("IACH"). The therapeutic potential of Zalmoxis® in haploidentical transplantation and of CAR T CD44v6 in blood tumours presented at the summit. ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.